Tumour cell PD-L1 expression is prognostic in patients with malignant pleural effusion: the impact of C-reactive protein and immune-checkpoint inhibition
Open Access
- 1 April 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Scientific Reports
- Vol. 10 (1), 1-10
- https://doi.org/10.1038/s41598-020-62813-2
Abstract
Malignant pleural effusion (MPE) confers dismal prognosis and has limited treatment options. While immune-checkpoint inhibition (ICI) proved clinical efficacy in a variety of malignancies, data on the prognostic role of PD-L1 in MPE is scarce. We retrospectively studied PD-L1 tumour proportion score and Ki-67 index in pleural biopsies or cytologies from 123 patients (69 lung cancer, 25 mesothelioma, and 29 extrathoracic primary malignancies). Additionally, the impact of C-reactive protein (CRP) and platelet count was also analysed. Median overall survival (OS) after MPE diagnosis was 9 months. Patients with PD-L1 positive tumours (≥1%) had significantly shorter OS than patients with negative PD-L1 status (p = 0.031). CRP and Ki-67 index were also prognostic and remained independent prognosticators after multivariate analysis. Interestingly, Ki-67 index and CRP influenced the prognostic power of PD-L1. Finally, patients receiving ICI tended to have a longer median OS and CRP - but not PD-L1 - was a significant prognosticator in this subgroup. In summary, histological and circulating biomarkers should also be taken into account as potential biomarkers in ICI therapy and they may have an impact on the prognostic power of PD-L1. Our findings might help personalizing immune-checkpoint inhibition for patients with MPE and warrant further prospective validation.This publication has 39 references indexed in Scilit:
- Monitoring efficacy of checkpoint inhibitor therapy in patients with non-small-cell lung cancerImmunotherapy, 2019
- Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or GreaterJournal of Clinical Oncology, 2019
- The next age of immunotherapy: optimisation, stratification and therapeutic synergiesBritish Journal of Cancer, 2018
- PD-L1 Expression of Tumor Cells, Macrophages, and Immune Cells in Non–Small Cell Lung Cancer Patients with Malignant Pleural EffusionJournal of Thoracic Oncology, 2018
- Intrathoracic solitary fibrous tumor – an international multicenter study on clinical outcome and novel circulating biomarkersScientific Reports, 2017
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung CancerThe New England Journal of Medicine, 2015
- Prognostic factors affecting survival in non‐small cell lung carcinoma patients with malignant pleural effusionsThe Clinical Respiratory Journal, 2015
- Predicting survival in malignant pleural effusion: development and validation of the LENT prognostic scoreThorax, 2014
- Clinical impact of ki-67 labeling index in non-small cell lung cancerLung Cancer, 2013
- Pretreatment Serum C-Reactive Protein Levels Predict Benefit From Multimodality Treatment Including Radical Surgery in Malignant Pleural MesotheliomaAnnals of Surgery, 2012